NCT06449833View on ClinicalTrials.gov

Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Type2 Diabetes MellitusNonalcoholic Fatty Liver Disease
Interventions
DRUG

Henagliflozein and Metformin

The experimental group will be treated with 10mg Henagliflozein and Metformin.

DRUG

Linagliptin and Metformin

The control group will be treated with 5mg Linagliptin and Metformin.

Trial Locations (1)

510000

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

Zhujiang Hospital

OTHER